$11.1 M

GALE Mkt cap, 22-Dec-2017
Galena Biopharma Net income (Q3, 2018)-290 K
Galena Biopharma Cash, 30-Sep-201810 M
Galena Biopharma EV1.3 M

Galena Biopharma Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

2.5m

Cost of goods sold

520.0k

Gross profit

2.0m

Gross profit Margin, %

79%

R&D expense

21.1m23.6m19.9m6.1m

General and administrative expense

14.6m10.6m12.0m15.1m

Operating expense total

36.3m34.2m31.9m21.2m

EBIT

(33.8m)(34.2m)(31.9m)

EBIT margin, %

(1361%)

Interest expense

807.0k760.0k3.5m462.0k

Interest income

807.0k

Pre tax profit

(75.6m)(38.6m)(10.9m)

Income tax expense

1.1m365.0k243.0k253.0k

Net Income

(76.7m)(63.9m)(23.5m)(23.8m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.2m2.2m2.3m1.6m2.8m3.4m

Cost of goods sold

301.0k331.0k347.0k247.0k393.0k468.0k

Gross profit

869.0k1.8m2.0m1.4m2.4m2.9m

Gross profit Margin, %

74%85%85%85%86%86%

R&D expense

3.5m6.8m8.1m7.2m5.9m7.3m5.4m6.2m3.6m2.4m2.0m951.0k1.8m1.6m1.7m

General and administrative expense

3.8m3.5m3.1m2.8m2.7m2.9m3.5m3.9m4.9m1.3m

Operating expense total

7.3m14.0m18.1m14.8m5.9m14.7m9.0m9.3m6.5m5.1m4.9m4.5m5.7m12.2m3.1m

EBIT

(6.9m)(11.8m)(15.8m)(13.2m)(11.1m)(11.3m)(9.0m)(9.3m)(6.5m)(5.1m)(4.9m)(4.5m)

EBIT margin, %

(589%)(545%)(677%)(815%)(405%)(333%)

Interest expense

314.0k314.0k314.0k297.0k242.0k207.0k91.0k519.0k1.4m973.0k687.0k565.0k96.0k122.0k74.0k

Interest income

314.0k314.0k314.0k297.0k242.0k207.0k91.0k

Pre tax profit

(8.1m)(2.5m)(19.9m)(6.2m)(5.9m)(290.0k)

Income tax expense

1.2m163.0k

Net Income

(9.3m)(2.5m)(19.9m)(6.2m)(10.5m)(15.7m)(16.5m)5.4m(6.9m)(11.7m)(8.4m)(6.1m)(8.0m)(6.1m)(290.0k)

Galena Biopharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

47.8m23.7m29.7m18.1m2.3m

Accounts Receivable

Inventories

386.0k655.0k581.0k

Current Assets

53.5m29.0m53.6m37.5m13.1m

Goodwill

5.9m6.1m5.9m5.9m1.9m

Total Assets

88.0m80.5m82.1m65.8m33.5m

Accounts Payable

2.7m2.3m1.6m840.0k11.7m

Short-term debt

2.1m3.9m4.7m16.4m8.4m

Current Liabilities

62.4m27.2m57.1m30.4m24.6m

Long-term debt

2.6m

Total Debt

2.1m4.7m16.4m11.0m

Total Liabilities

82.1m68.6m37.2m31.5m

Additional Paid-in Capital

188.6m256.4m296.7m335.4m56.3m

Retained Earnings

178.9m215.5m279.4m302.9m(54.2m)

Total Equity

5.9m37.1m13.5m28.7m2.1m

Debt to Equity Ratio

0.4 x0.6 x5.3 x

Debt to Assets Ratio

0.1 x0.2 x0.3 x

Financial Leverage

14.9 x2.2 x6.1 x2.3 x16.2 x

Galena Biopharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(76.7m)(36.6m)(39.0m)(11.1m)(23.8m)

Depreciation and Amortization

452.0k355.0k142.0k

Accounts Receivable

(3.7m)

Inventories

(386.0k)

Accounts Payable

684.0k(289.0k)(757.0k)8.4m

Cash From Operating Activities

(28.9m)(48.2m)(44.9m)(11.0m)

Cash From Investing Activities

(12.0m)10.4m(1.1m)1.8m

Long-term Borrowings

(3.9m)(5.6m)

Cash From Financing Activities

55.9m43.8m34.3m5.5m

Galena Biopharma Ratios

USDY, 2018

Financial Leverage

2.1 x
Report incorrect company information

Galena Biopharma Employee Rating

2.63 votes
Culture & Values
2.7
Work/Life Balance
2.4
Senior Management
2.6
Salary & Benefits
3.4
Career Opportunities
3.4
Source